On July 1, Formycon AG announced the FDA approval of the third aflibercept biosimilar; the new drug will be called Ahzantive® (aflibercept-mrbb). Two biosimilars were approved in late May, and the market for Eylea® biosimilars may get even more crowded: Amgen and Celltrion are awaiting FDA decisions in 2024 on their own biosimilar candidates. Formycon … Continue reading Formycon AG Receives FDA Nod for Ahzantive, an Aflibercept Biosimilar